mevalonic acid and Age-Related Osteoporosis

mevalonic acid has been researched along with Age-Related Osteoporosis in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (80.00)29.6817
2010's3 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chin, KY; Ghafar, NA; Hasan, WNW; Jolly, JJ; Soelaiman, IN1
Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Li, M; Liu, YJ; Shao, C; Wang, C; Yue, H; Zhang, H; Zhang, ZL; Zheng, H1
Hanayama, R; Kunugiza, Y; Makino, H; Morishita, R; Nakagami, H; Osako, MK; Rakugi, H; Shimizu, H; Tomita, T; Tsukamoto, I; Yoshikawa, H1
Aoyama, K; Kimoto, A; Minamide, T; Miyata, K; Mori, H; Mori, M; Nozaki, K; Sasamata, M; Shimizu, K; Shimokawa, K; Suzuki, H; Tanaka, M; Usui, T; Yamamotoya, H1
Capecchi, PL; Capperucci, C; Ferrata, P; Frediani, B; Galeazzi, M; Laghi-Pasini, F; Lazzerini, PE; Niccolini, S; Spreafico, A1
Komatsu, S; Ohta, T; Tokutake, N1
Reszka, AA; Rodan, GA1
Ishimi, Y1
Taguchi, M; Takeuchi, Y1
Russell, RG1
Inaba, M; Nishizawa, Y; Yamada, S1
Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M1
Mundy, GR1
Yoneda, T1
Cruz, AC; Gruber, BL1

Reviews

11 review(s) available for mevalonic acid and Age-Related Osteoporosis

ArticleYear
Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
    Endocrine, metabolic & immune disorders drug targets, 2018, Volume: 18, Issue:5

    Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Drug Development; Drug Discovery; Humans; Mevalonic Acid; Molecular Targeted Therapy; Osteoporosis; Protein Prenylation; Signal Transduction

2018
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 134, Issue:3

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures

2009
[Pharmacological and clinical properties of alendronate sodium hydrate].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2002, Volume: 120, Issue:6

    Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clinical Trials as Topic; Depression, Chemical; Fractures, Bone; GTP-Binding Proteins; Humans; Mevalonic Acid; Osteoclasts; Osteoporosis; Protein Prenylation

2002
Bisphosphonate mechanism of action.
    Current rheumatology reports, 2003, Volume: 5, Issue:1

    Topics: Apoptosis; Bone Resorption; Diphosphonates; Humans; Mevalonic Acid; Osteoclasts; Osteoporosis

2003
[The role of mevalonate pathway in osteogenic cells].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2

    Topics: Acyl Coenzyme A; Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption; Cell Differentiation; Diphosphonates; Fractures, Bone; GTP-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Polyisoprenyl Phosphates; Protein Prenylation; Sesquiterpenes; Signal Transduction; Transforming Growth Factor beta

2004
[Anabolic effects of statin and beta-blocker on bone metabolism].
    Clinical calcium, 2004, Volume: 14, Issue:12

    Topics: Adrenergic beta-Antagonists; Animals; Bone and Bones; Bone Density; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Risk; Stimulation, Chemical; Sympathetic Nervous System

2004
Bisphosphonates: from bench to bedside.
    Annals of the New York Academy of Sciences, 2006, Volume: 1068

    Topics: Bone Density Conservation Agents; Humans; Mevalonic Acid; Organophosphonates; Osteitis Deformans; Osteoporosis

2006
[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9

    Topics: Alendronate; Apolipoprotein A-I; Arthritis, Rheumatoid; Atherosclerosis; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholesterol, HDL; Humans; Mevalonic Acid; Osteoporosis

2007
Statins and their potential for osteoporosis.
    Bone, 2001, Volume: 29, Issue:6

    Topics: Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteoblasts; Osteoporosis

2001
[Stimulation of bone formation by anti-hyperlipidemic agent statins and its mechanism of action].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3

    Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Mevalonic Acid; Osteogenesis; Osteoporosis; Stimulation, Chemical; Transforming Growth Factor beta

2002
Statins and osteoporosis: can these lipid-lowering drugs also bolster bones?
    Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:4

    Topics: Animals; Bone Density; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Osteogenesis; Osteoporosis; Transforming Growth Factor beta

2002

Other Studies

4 other study(ies) available for mevalonic acid and Age-Related Osteoporosis

ArticleYear
Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:2

    Topics: Aged; Alendronate; Alleles; Asian People; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Haplotypes; Humans; Lumbar Vertebrae; Mevalonic Acid; Osteoporosis; Phosphotransferases (Alcohol Group Acceptor); Polymorphism, Single Nucleotide; Postmenopause

2015
Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action.
    International journal of molecular medicine, 2009, Volume: 23, Issue:5

    Topics: Animals; Animals, Newborn; Antioxidants; Cell Differentiation; Cells, Cultured; Diet; Down-Regulation; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Female; Fluvastatin; Fructose; Indoles; Insulin Resistance; Mevalonic Acid; Osteoclasts; Osteoporosis; Rabbits; Rats; Rats, Wistar; Signal Transduction

2009
Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
    Joint bone spine, 2013, Volume: 80, Issue:2

    Topics: Aged; Bone Resorption; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Media; Diterpenes; Farnesol; Femur Head; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Mevalonic Acid; Middle Aged; Osteoblasts; Osteoporosis; Osteoprotegerin; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Terpenes

2013
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
    Biochemical and biophysical research communications, 2000, May-19, Volume: 271, Issue:3

    Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured

2000